Sanofi-aventis and Columbia University to Collaborate on Diabetes Research

Sanofi-aventis and Columbia University Medical Center announced a three-year research collaboration for the development of innovative diabetes medicines. This research collaboration, with the laboratory of Dr. Gerard Karsenty, will investigate the role of the osteoblast-secreted peptide, osteocalcin, in diabetes management… Read more

Sanofi-aventis and UCSF to Collaborate on Development of Diabetes Therapies

The University of California, San Francisco (UCSF) and sanofi-aventis have formed two new research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The first collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation… Read more

Sanofi-aventis’ Once-Daily Type 2 Diabetes Drug Lixisenatide Shows Significant Improvement in Glucose Control

Sanofi-aventis announced the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden… Read more

JDRF and Sanofi-aventis Join Forces in Search of Cure for Type 1 Diabetes

Sanofi-aventis and the Juvenile Diabetes Research Foundation (JDRF) announced a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease – both those living with the disease and the newly diagnosed – as well as preventing diabetes in those at risk… Read more

Sanofi-Aventis Diabetes Monotherapy Meets Phase III Study Endpoint Successfully

Sanofi-aventis announced the results of the first placebo-controlled study of the GetGoal Phase III clinical trial program of lixisenatide (AVE0010), a once-daily GLP-1 agonist developed for patients with type 2 diabetes.
The 12-week study involved 361 patients with type 2 diabetes not currently receiving glucose-lowering therapy and with HbA1c between 7 and 10%… Read more

Sanofi-Aventis and CureMD sign $335M Deal on Diabetes Cure Development

Sanofi-aventis announced that it has signed a global license agreement with CureDM Group on a novel human peptide, Pancreate™, which could restore a patients’ ability to produce insulin and other pancreatic hormones in both type 1 and type 2 diabetes. Pancreate™ is a bioactive peptide sequence of a naturally occurring human protein that has been shown… Read more

Sanofi-aventis & AgaMatrix to Develop New Blood Glucose Monitoring Solutions

Sanofi-aventis announced that they have signed an agreement with AgaMatrix Inc. for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes care with the aim to simplify patients’ and healthcare providers’ diabetes management experience…. Read more

Senator Asks Drug Companies to Explain High Prices

Senator Herb Kohl (D), chair of the Special Committee on Aging, sent letters to AstraZeneca, GlaxoSmithKline, Eli Lilly, Novartis, Pfizer, and Sanofi-Aventis asking them to explain why Americans on average pay twice as much as people in other industrialized countries for prescription drugs… Read more

Subscribe to our Newsletter

Hide me